Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

 

Sufficient group

Insufficient group

Total

P-value

n = 34

n = 63

n = 97

25(OH)D (ng/mL)

38 (34, 43)

21 (16, 24)

24 (18, 35)

<0.001

Male sex

74 % (25)

65 % (41)

68 % (66)

0.53

Age (years)

45 (38, 50)

47 (38, 53)

45 (38, 52)

0.87

White race/ethnicity

50 % (17)

54 % (34)

53 % (51)

0.87

Nadir CD4+ T lymphocyte (cells/mm3)

185 (97, 230)

143 (49, 242)

170 (71, 236)

0.39

  ≥ 350

3 % (1)

3 % (2)

3 % (3)

 

 200–349

38 % (12)

34 % (21)

36 % (33)

 

 50–199

53 % (17)

36 % (22)

42 % (39)

 

  < 50

6 % (2)

26 % (16)

19 % (18)

 

Baseline CD4+ T lymphocyte (cells/mm3)

650 (437, 754)

688 (499, 792)

673 (465, 775)

0.39

  ≥ 500

66 % (19)

74 % (43)

72 % (62)

 

 350–499

24 % (7)

16 % (9)

18 % (16)

 

  < 350

10 % (3)

10 % (6)

10 % (9)

 

Time on ART (years)

5 (4, 5)

5 (5, 6)

5 (4, 6)

0.40

Time on TDF (years)

3 (1, 4)

3 (0, 5)

3 (1, 5)

0.42

Time on AZT (years)

0 (0, 4)

0 (0, 5)

0 (0, 5) 4(1.3,4.9)

0.06

Time on EFV (years)

3 (0, 5)

4 (2, 5)

4 (1, 5)

0.10

Time on PI (years)

2 (0, 5)

0 (0, 2)

0 (0, 5)

0.10

Current TDF use

77 % (26)

68 % (43)

71 % (69)

0.54

Current AZT use

24 % (8)

35 % (22)

31 % (30)

0.35

Current EFV use

65 % (22)

73 % (46)

70 % (68)

0.54

Current PI use

35 % (12)

24 % (15)

28 % (27)

0.33

DXA classificationa

   

0.17

 Normal

32 % (6)

29 % (10)

30 % (16)

 

 Osteopenia

63 % (12)

46 % (16)

52 % (28)

 

 Osteoporosis

5 % (1)

26 % (9)

18 % (10)

 

 Any bone diseaseb

68 % (13)

71 % (25)

70 % (38)

0.10

BMIa (kg/m2)

25 (23, 27)

25 (24, 28)

25 (23, 27)

0.46

  < 18.5

5 % (1)

0 (0)

2 % (1)

 

 18.5–24.9

47 % (9)

51 % (18)

50 % (27)

 

 25.0–29.9

47 % (9)

31 % (11)

11 % (6)

 

  ≥ 30.0

0 (0)

17 % (6)

37 % (20)

 

C-reactive protein (mg/dL)

0.2 (0.3, 0.9)

0.3 (0.2, 0.6)

0.3 (0.2, 0.6)

0.56

Glucose (mg/dL)

89 (81, 95)

88 (81, 93)

88 (81, 93)

0.73

HbA1c (%)

5.5 (5.3, 5.7)

5.5 (5.3, 5.7)

5.5 (5.3, 5.7)

0.84

Triglycerides (mg/dL)

108 (76, 181)

121 (86, 185)

120 (80, 184)

0.55

Total cholesterol (mg/dL)

195 (171, 223)

196 (173, 217)

196 (172, 221)

0.82

HDL (mg/dL)

45 (37, 51)

47 (39, 58)

47 (39, 58)

0.60

LDL (mg/dL)

117 (93, 140)

120 (92, 145)

118 (92, 143)

0.89

  1. Median (interquartile range) or percent (n) presented
  2. 25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitor, DXA dual-energy X-ray absorptiometry, BMI body mass index, HbA1c glycated hemoglobin
  3. aData available for 54 patients (19 in sufficiency group, 35 in insufficiency group)
  4. bAny bone disease aggregates osteoporosis and osteopenia
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us